본문
Interview with CEO Kim Jeong-min June 20, 2024
DM5167, a second-generation PARP inhibitor, is undergoing a phase 1 clinical trial in patients with advanced breast cancer. Partial remission was confirmed at the lowest dose.
It is superior to AstraZeneca in efficacy and safety.
High brain penetration rate, excellent effect on brain metastases
Optimistic about license-out contract next year, when clinical results are released.
Dementia drug candicdate DM3159 to enter preclinical trials this year
Neuroregeneration and improved cognitive function confirmed in rat experiments.
Potential license-out deal based on preclinical data alone